Overview

Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
Escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kolon Life Science